Kaleido Biosciences, Inc. (KLDO)
Apr 18, 2022 - KLDO was delisted (reason: ceased operations)
0.290
0.000 (0.00%)
At close: Apr 14, 2022 12:00 AM
0.300
0.010 (3.552%)
After-hours:Apr 14, 2022 7:59 PM EDT
Company Description
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies.
The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease.
It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases.
The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Kaleido Biosciences, Inc.
| Country | United States |
| Founded | 2015 |
| IPO Date | Feb 28, 2019 |
| Industry | Pharmaceuticals |
| Sector | Health Care |
| Employees | 82 |
Contact Details
Address: 65 Hayden Avenue Lexington, MA 02421 United States | |
| Phone | 617 674 9000 |
| Website | kaleido.com |
Stock Details
| Ticker Symbol | KLDO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | US Dollars |
| IPO Price | $15.00 |
| CIK Code | 0001751299 |
Key Executives
| Name | Position |
|---|---|
| Jerald Korn J.D. | Consultant |
| Kimberly Hocknell | Senior Vice President of Technical Operations |
| Susan Stewart J.D. | Chief Regulatory Affairs ? Advisor |
| Dr. Mark A. Wingertzahn Ph.D. | Senior Vice President of Research & Development and Head of Development |
| Dr. Alison Long M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 10, 2022 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals |
| May 6, 2022 | 15-12B | Securities registration termination [Section 12(b)] |
| May 2, 2022 | EFFECT | Notice of Effectiveness |
| Apr 25, 2022 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 25, 2022 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 25, 2022 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 25, 2022 | POS AM | Post-Effective amendments for registration statement |
| Apr 18, 2022 | 25 | Notification of the removal from listing and registration of matured, redeemed or retired securities |
| Apr 8, 2022 | 8-K | Current report |
| Mar 31, 2022 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| View All SEC Filings | ||